First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).Johanna C. Bendell, Johann S. de Bono, Lawrence Fong et al.|Journal of Clinical Oncology|2020Cited by 20
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared <i>KRAS</i> and <i>TP53</i> mutations expressed by solid tumors in first-in-human phase 1 study.Maria Pia Morelli, Scott Kopetz, Nathan Demars et al.|Journal of Clinical Oncology|2023Cited by 12